Leukemia, Mast-Cell - 25 Studies Found
Completed |
: Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD : Leukemia, Mast-Cell : 2005-09-14 :
|
Active, not recruiting |
: Phase II Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia :
: Drug: Midostaurin Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC i |
Recruiting |
: Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia :
: Drug: brentuximab vedotin Brentuximab vedotin is an antibody with a covalently attached toxin. The antib |
Active, not recruiting |
: Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia : Leukemia : 2008-10-28 : Drug: Midostaurin (PKC412) Midostaurin was provided as 25 mg soft gelatin capsules for oral administrati |
Recruiting |
: Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis :
: |
Recruiting |
: Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies :
|
Completed |
: Patient-Reported Outcome Questionnaire for Systemic Mastocytosis :
|
Recruiting |
: Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia :
|
Completed |
: Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies :
: |
Completed |
: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia :
: |